Young-Woo Kim1, Mi-Jung Kim1, Keun Won Ryu1, Hyeong-Seok Lim2,3, Jun Ho Lee1, Sun-Young Kong2, Jong Seok Lee1, Il Ju Choi1, Chan Gyoo Kim1, Jong Yeul Lee1, Soo-Jeong Cho1, Myeong-Cherl Kook1, Young-Iee Park1, Seok-Ki Kim4, Sook Ryun Park5,6. 1. Center for Gastric Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi, Republic of Korea. 2. Department of Laboratory Medicine, Center for Diagnostic Oncology, Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi, Republic of Korea. 3. Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. 4. Department of Nuclear Medicine, Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi, Republic of Korea. 5. Center for Gastric Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi, Republic of Korea. sukryun73@hanmail.net. 6. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro, 43-gil, Songpa-gu, Seoul, 138-736, Republic of Korea. sukryun73@hanmail.net.
Abstract
BACKGROUND: We conducted a phase II study to evaluate the efficacy and safety of perioperative S-1 plus docetaxel in locally advanced gastric cancer (LAGC) and to investigate the association between CYP2A6 genotype and outcome. METHODS: Patients with LAGC [clinical stage III-IV (M0) by the Japanese staging system] received three cycles of pre- and postoperative chemotherapy (S-1 40 mg/m(2) twice daily on days 1-14; intravenous docetaxel 35 mg/m(2) on days 1 and 8, every 3 weeks) followed by gastrectomy with D2 dissection. We also performed a pharmacokinetic and CYP2A6 genotyping study (*1, *4, *7, *9, *10) for S-1. RESULTS: From October 2006 to June 2008, 44 patients entered the study. 43 eligible patients completed preoperative chemotherapy and 40 completed postoperative chemotherapy. The most common G3/4 toxicities during pre- and postoperative chemotherapy were neutropenia, stomatitis, and abdominal pain. The clinical response rate by RECIST was 74.4 % (95 % CI, 61.4-87.4 %), and the R0 resection rate was 97.7 %. Clinical downstaging in T or N occurred in 41.9 % of patients. The 3-year progression-free survival (PFS) rate was 62.8 % and 5-year overall survival (OS) rate was 69.6 %. PFS and OS differed significantly according to clinical response, clinical downstaging, and CYP2A6 genotype. Patients with CYP2A6 variant/variant genotypes had a higher tegafur C max and worse survival than those with wild/wild or wild/variant genotypes. CONCLUSION: Perioperative S-1 plus docetaxel is active with a manageable toxicity in patients with LAGC receiving D2 surgery. Clinical tumor response, clinical downstaging, and CYP2A6 genotype may predict efficacy.
BACKGROUND: We conducted a phase II study to evaluate the efficacy and safety of perioperative S-1 plus docetaxel in locally advanced gastric cancer (LAGC) and to investigate the association between CYP2A6 genotype and outcome. METHODS:Patients with LAGC [clinical stage III-IV (M0) by the Japanese staging system] received three cycles of pre- and postoperative chemotherapy (S-1 40 mg/m(2) twice daily on days 1-14; intravenous docetaxel 35 mg/m(2) on days 1 and 8, every 3 weeks) followed by gastrectomy with D2 dissection. We also performed a pharmacokinetic and CYP2A6 genotyping study (*1, *4, *7, *9, *10) for S-1. RESULTS: From October 2006 to June 2008, 44 patients entered the study. 43 eligible patients completed preoperative chemotherapy and 40 completed postoperative chemotherapy. The most common G3/4 toxicities during pre- and postoperative chemotherapy were neutropenia, stomatitis, and abdominal pain. The clinical response rate by RECIST was 74.4 % (95 % CI, 61.4-87.4 %), and the R0 resection rate was 97.7 %. Clinical downstaging in T or N occurred in 41.9 % of patients. The 3-year progression-free survival (PFS) rate was 62.8 % and 5-year overall survival (OS) rate was 69.6 %. PFS and OS differed significantly according to clinical response, clinical downstaging, and CYP2A6 genotype. Patients with CYP2A6 variant/variant genotypes had a higher tegafur C max and worse survival than those with wild/wild or wild/variant genotypes. CONCLUSION: Perioperative S-1 plus docetaxel is active with a manageable toxicity in patients with LAGC receiving D2 surgery. Clinical tumor response, clinical downstaging, and CYP2A6 genotype may predict efficacy.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: D Vallböhmer; A H Hölscher; P M Schneider; M Schmidt; M Dietlein; E Bollschweiler; S Baldus; H Alakus; J Brabender; R Metzger; S P Mönig Journal: J Surg Oncol Date: 2010-08-01 Impact factor: 3.454
Authors: Sook Ryun Park; Min Ju Kim; Keun Won Ryu; Jun Ho Lee; Jong Seok Lee; Byung-Ho Nam; Il Ju Choi; Young-Woo Kim Journal: Ann Surg Date: 2010-03 Impact factor: 12.969
Authors: J A Ajani; P F Mansfield; P M Lynch; P W Pisters; B Feig; P Dumas; D B Evans; I Raijman; K Hargraves; S Curley; D M Ota Journal: J Clin Oncol Date: 1999-08 Impact factor: 44.544
Authors: Katja Ott; Ken Herrmann; Florian Lordick; Hinrich Wieder; Wolfgang A Weber; Karen Becker; Andreas K Buck; Martin Dobritz; Ulrich Fink; Kurt Ulm; Tibor Schuster; Markus Schwaiger; Jörg-Rüdiger Siewert; Bernd J Krause Journal: Clin Cancer Res Date: 2008-04-01 Impact factor: 12.531
Authors: M Dank; J Zaluski; C Barone; V Valvere; S Yalcin; C Peschel; M Wenczl; E Goker; L Cisar; K Wang; R Bugat Journal: Ann Oncol Date: 2008-06-16 Impact factor: 32.976
Authors: S R Park; S-Y Kong; B-H Nam; I J Choi; C G Kim; J Y Lee; S J Cho; Y W Kim; K W Ryu; J H Lee; J Rhee; Y-I Park; N K Kim Journal: Br J Cancer Date: 2011-03-01 Impact factor: 7.640